Aryl hydrocarbon receptor inhibition downregulates the TGF-beta/Smad pathway in human glioblastoma cells

D Gramatzki1, G Pantazis, J Schittenhelm

  • 1Laboratory of Molecular Neuro-Oncology, Department of General Neurology and Hertie Institute for Clinical Brain Research, University of Tuebingen, Tuebingen, Germany.

Oncogene
|May 26, 2009
PubMed

Insights

The aryl hydrocarbon receptor (AhR) promotes malignant glioma growth by upregulating transforming growth factor-beta (TGF-beta) signaling. Inhibiting AhR reduces glioma cell survival and invasiveness, suggesting AhR as a potential therapeutic target.

Area of Science:

  • Molecular biology
  • Oncology
  • Cell signaling

Background:

  • The aryl hydrocarbon receptor (AhR) is a transcription factor implicated in cancerogenesis and transforming growth factor-beta (TGF-beta) signaling.
  • TGF-beta is a key mediator of the malignant phenotype in human gliomas.

Purpose of the Study:

  • To investigate the expression and function of AhR in glioma cells.
  • To determine the role of AhR in TGF-beta signaling within gliomas.
  • To evaluate AhR as a potential therapeutic target for malignant gliomas.

Main Methods:

  • Immunohistochemistry to detect AhR expression in human gliomas.
  • Treatment with an AhR agonist (3-methylcholanthrene) and antagonist (CH-223191).
  • AhR gene silencing using small interfering RNA.
  • Analysis of TGF-beta1, TGF-beta2, latent TGF-beta-binding protein-1, and CYP1A1 mRNA and protein levels.
  • Assessment of glioma cell clonogenic survival and invasiveness.

Main Results:

  • AhR was expressed in glioma cells in vitro and detected in vivo, with nuclear localization in glioblastomas.
  • AhR activation upregulated its target gene CYP1A1.
  • AhR inhibition or silencing reduced TGF-beta1, TGF-beta2, and latent TGF-beta-binding protein-1 levels in malignant glioma cells.
  • AhR antagonism decreased glioma cell clonogenic survival and invasiveness.
  • AhR negatively regulated TGF-beta signaling in non-neoplastic astrocytes.

Conclusions:

  • Altered AhR regulation of the TGF-beta/Smad pathway is involved in glioma pathogenesis.
  • AhR antagonism shows potential for treating malignant gliomas.
  • AhR may be a therapeutic target for diseases involving pathological TGF-beta activity.

Related Concept Videos

TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors are of three kinds RI, RII, and RIII. The RI...
Receptor Downregulation in MVBs01:15

Receptor Downregulation in MVBs

Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that  lead to cell proliferation, migration, and differentiation. Overexpression of EGFR  stimulates cells to proliferate. Excessive  EGFR activation may...
Hedgehog Signaling Pathway02:33

Hedgehog Signaling Pathway

The Hedgehog gene (Hh) was first discovered due to its control of the growth of disorganized, hair-like bristles phenotype in Drosophila, much like hedgehog spines. Hh plays a crucial role in the development of organs and the maintenance of homeostasis in both invertebrates and vertebrates. However, while Drosophila has only one Hh protein, mammals have multiple functional Hedgehog proteins - Sonic (Shh), Desert (Dhh), and Indian Hedgehog (Ihh). All of these homologous proteins have adapted to...